1173245-11-8

Basic information

• Product Name: (1S)-2-benzyl 1-methyl 5-oxo-3,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate
• Synonyms: (1S)-2-benzyl 1-methyl 5-oxo-3,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate
• CAS NO: 1173245-11-8
• Molecular Formula: C17H17NO5
• Molecular Weight: 315.32058
• Mol File: 1173245-11-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1S)-2-benzyl 1-methyl 5-oxo-3,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1S)-2-benzyl 1-methyl 5-oxo-3,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate(1173245-11-8)
• EPA Substance Registry System: (1S)-2-benzyl 1-methyl 5-oxo-3,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate(1173245-11-8)

Safety Data

• Hazardous Substances Data: 1173245-11-8(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 792948-19-7 (2S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl)butanoate 
• 792948-18-6 (S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylthio)butanoate 
• 792948-36-8 (S)-4-methylsulfanyl-2-prop-2-ynylaminobutyric acid methyl ester 
• 201230-82-2 carbon monoxide 
• 792948-17-5 (S)-2-(Benzyloxycarbonyl-prop-2-ynyl-amino)-but-3-enoic acid methyl ester 

Downstream Products

• 1173245-10-7 (1S,3aS,6aR)-2-benzyl 1-methyl 5-oxohexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate 
• 1173245-13-0 (1S,3aS,6aR)-2-benzyl 1-methyl 5-hydroxyhexahydrocyclopenta[c]pyrrole1,2(1H)-dicarboxylate 

Relevant articles and documents

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.